SMT202200471T1 - Seladelpar per il trattamento della colangite biliare primitiva - Google Patents

Seladelpar per il trattamento della colangite biliare primitiva

Info

Publication number
SMT202200471T1
SMT202200471T1 SM20220471T SMT202200471T SMT202200471T1 SM T202200471 T1 SMT202200471 T1 SM T202200471T1 SM 20220471 T SM20220471 T SM 20220471T SM T202200471 T SMT202200471 T SM T202200471T SM T202200471 T1 SMT202200471 T1 SM T202200471T1
Authority
SM
San Marino
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
SM20220471T
Other languages
English (en)
Italian (it)
Inventor
Pol Boudes
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of SMT202200471T1 publication Critical patent/SMT202200471T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20220471T 2016-05-31 2017-04-26 Seladelpar per il trattamento della colangite biliare primitiva SMT202200471T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
EP17722943.2A EP3463328B1 (en) 2016-05-31 2017-04-26 Seladelpar for the treatment of primary biliary cholangitis
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
SMT202200471T1 true SMT202200471T1 (it) 2023-01-13

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220471T SMT202200471T1 (it) 2016-05-31 2017-04-26 Seladelpar per il trattamento della colangite biliare primitiva

Country Status (27)

Country Link
US (5) US10272058B2 (enExample)
EP (1) EP3463328B1 (enExample)
JP (1) JP7079735B2 (enExample)
KR (1) KR102408288B1 (enExample)
CN (1) CN109195594A (enExample)
AU (1) AU2017274293B2 (enExample)
BR (1) BR112018074147A2 (enExample)
CA (1) CA3024155C (enExample)
CY (1) CY1125465T1 (enExample)
DK (1) DK3463328T3 (enExample)
ES (1) ES2921230T3 (enExample)
HR (1) HRP20220903T1 (enExample)
HU (1) HUE059838T2 (enExample)
IL (1) IL263372B2 (enExample)
LT (1) LT3463328T (enExample)
MX (1) MX390417B (enExample)
NZ (1) NZ748721A (enExample)
PL (1) PL3463328T3 (enExample)
PT (1) PT3463328T (enExample)
RS (1) RS63345B1 (enExample)
RU (1) RU2765460C2 (enExample)
SG (1) SG11201810123SA (enExample)
SI (1) SI3463328T1 (enExample)
SM (1) SMT202200471T1 (enExample)
UA (1) UA122719C2 (enExample)
WO (1) WO2017209865A1 (enExample)
ZA (1) ZA201808360B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210092754A (ko) * 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료
HUE066653T2 (hu) * 2021-02-01 2024-08-28 Cymabay Therapeutics Inc Cholangiopathiák kezelése seladelparral

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
MX2011004077A (es) 2008-10-17 2011-08-17 Metabolex Inc Metodos para reducir particulas de ldl densas, pequeñas.
NZ807894A (en) * 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2011235301B2 (en) 2010-03-30 2013-07-18 Novartis Ag Uses of DGAT1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
PL3129018T3 (pl) 2014-04-11 2020-05-18 Cymabay Therapeutics, Inc. Leczenie NAFLD i NASH
SG11201610243YA (en) 2014-06-26 2017-01-27 Cymabay Therapeutics Inc Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2019067373A1 (en) 2017-09-26 2019-04-04 Cymabay Therapeutics, Inc. TREATMENT OF CHOLESTATIC PRURIT
MX2021005725A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
KR20210092754A (ko) 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료

Also Published As

Publication number Publication date
SG11201810123SA (en) 2018-12-28
BR112018074147A2 (pt) 2019-03-06
WO2017209865A1 (en) 2017-12-07
US20200061006A1 (en) 2020-02-27
IL263372A (en) 2018-12-31
ES2921230T3 (es) 2022-08-22
US20210000774A1 (en) 2021-01-07
LT3463328T (lt) 2022-08-10
SI3463328T1 (sl) 2022-08-31
US10813895B2 (en) 2020-10-27
DK3463328T3 (da) 2022-07-04
MX2018014915A (es) 2019-04-24
US20170340589A1 (en) 2017-11-30
US10478411B2 (en) 2019-11-19
PL3463328T3 (pl) 2022-10-03
US11000494B2 (en) 2021-05-11
KR102408288B1 (ko) 2022-06-10
US20210220305A1 (en) 2021-07-22
AU2017274293A1 (en) 2018-12-13
NZ748721A (en) 2022-04-29
AU2017274293B2 (en) 2022-03-31
JP7079735B2 (ja) 2022-06-02
CA3024155C (en) 2023-10-10
JP2019518022A (ja) 2019-06-27
RU2018146504A3 (enExample) 2020-07-27
PT3463328T (pt) 2022-07-07
CN109195594A (zh) 2019-01-11
RS63345B1 (sr) 2022-07-29
HUE059838T2 (hu) 2023-01-28
US20190255004A1 (en) 2019-08-22
CY1125465T1 (el) 2025-05-09
CA3024155A1 (en) 2017-12-07
ZA201808360B (en) 2020-02-26
RU2765460C2 (ru) 2022-01-31
HRP20220903T1 (hr) 2022-10-14
RU2018146504A (ru) 2020-07-09
UA122719C2 (uk) 2020-12-28
US11596614B2 (en) 2023-03-07
US10272058B2 (en) 2019-04-30
MX390417B (es) 2025-03-20
EP3463328B1 (en) 2022-06-15
EP3463328A1 (en) 2019-04-10
KR20190015363A (ko) 2019-02-13
IL263372B2 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
IL275482A (en) Asketamine for the treatment of depression
HUE071511T2 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
IL279627A (en) A method for treating depression
IL266012A (en) Combination therapy for c3 inhibition
ZA201903649B (en) Treatment for primary biliary cholangitis
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
SI3506904T1 (sl) Zdravljenje demence
SI3261726T1 (sl) Sestavek za zdravljenje aken
ZA201800869B (en) Continuous process for the treatment of wastewater
AP2016009497A0 (en) Process for the treatment of high sulphate waters
SMT202200471T1 (it) Seladelpar per il trattamento della colangite biliare primitiva
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
IL253617A0 (en) Snekribirock for the treatment of leprosy
PL3431656T3 (pl) Sposób obróbki kamieni tłuczniowych
ZA202001536B (en) Method for the treatment of wastewaters
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
PL3292226T3 (pl) Sposób obróbki szlamu zawierającego żelazo
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
ZA201906542B (en) Process for the treatment of wastewater
HK40019899A (en) Compounds and methods for treatment of primary biliary cholangitis
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
ZA201704589B (en) Compounds for the treatment of cancer
GB201701933D0 (en) New methods for the treatment of hyperglycaemia
PT3524255T (pt) Composição para o tratamento do acne